NL-OMON45219CompletedPhase 3
A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - D4191C00004 - ARCTIC
Astra Zeneca0 sites18 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 18
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 64 (—)
Inclusion Criteria
- •- At least 18 years of age
- •- Documented evidence of NSCLC (Stage IIIB/ IV disease)
- •- Disease progression or recurrence after both a platinum-baed chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC
- •- World Health Organization (WHO) Performance Status of 0 or 1
- •- Estimated life expectancy more than 12 weeks
Exclusion Criteria
- •- Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
- •- Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
- •- Active or prior documented autoimmune disease within the past 2 years
- •- Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including acute or chronic hepatitis B, C and HIV
- •- Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy
- •- Known EGFR TK activating mutations or ALK rearrangements. Patients with EGFR TK inactivating mutations, e.g. exon 20, are eligible
- •- Any prior Grade *3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
- •- Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2014-000338-46-GBAstraZeneca AB1,300
Active, not recruiting
Phase 1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)MedDRA version: 21.1Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-000338-46-PLAstraZeneca AB1,300
Active, not recruiting
Phase 1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)MedDRA version: 21.1Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-000338-46-DEAstraZeneca AB1,300
Active, not recruiting
Phase 1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2014-000338-46-HUAstraZeneca AB1,300
Active, not recruiting
Phase 1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2014-000338-46-NLAstraZeneca AB1,000